Topical Treatment Of Actinic Keratosis Therapeutics
1. Picato patent expiration
Treatment: Treatment of actinic keratosis; Use of ingenol mebutate to treat actinic keratosis; To stimulate the immune system to induce t cell proliferation; To inhibit the proliferative activity of neoplastic c...
PICATO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6787161 | LEO LABS | Anti-cancer compounds |
Aug, 2018
(7 years ago) | |
| US8536163 | LEO LABS | Therapeutic compositions |
Dec, 2026
(11 months from now) | |
| US6432452 | LEO LABS | Anti-cancer compounds |
Aug, 2018
(7 years ago) | |
| US6844013 | LEO LABS | Methods of stimulating the immune system |
Dec, 2018
(7 years ago) | |
| US7410656 | LEO LABS | Anti-cancer compounds |
Aug, 2018
(7 years ago) | |
| US8716271 | LEO LABS | Therapeutic compositions |
Dec, 2026
(11 months from now) | |
| US9861603 | LEO LABS | Therapeutic compositions |
Dec, 2026
(11 months from now) | |
| US8735375 | LEO LABS | Therapeutic compositions |
Dec, 2026
(11 months from now) | |
| US9820959 | LEO LABS | Therapeutic compositions |
Dec, 2026
(11 months from now) | |
| US9789078 | LEO LABS | Method of topically treating actinic keratosis with ingenol mebutate cycle therapy |
May, 2033
(7 years from now) | |
| US9833429 | LEO LABS | Therapeutic compositions |
Dec, 2026
(11 months from now) | |
| US8377919 | LEO LABS | Therapeutic compositions |
Dec, 2026
(11 months from now) | |
| US8372827 | LEO LABS | Therapeutic compositions |
Dec, 2026
(11 months from now) | |
| US8372828 | LEO LABS | Therapeutic compositions |
Dec, 2026
(11 months from now) | |
| US9833428 | LEO LABS | Therapeutic compositions |
Dec, 2026
(11 months from now) | |
| US8278292 | LEO LABS | Therapeutic compositions |
Jul, 2027
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 23, 2017 |
| M(M-169) | Nov 19, 2018 |
Drugs and Companies using INGENOL MEBUTATE ingredient
NCE-1 date: 24 January, 2016
Market Authorisation Date: 23 January, 2012
Dosage: GEL
How can I launch a generic of PICATO before it's drug patent expiration?
More Information on Dosage
PICATO family patents
